Canine parvovirus type 2 (CPV-2), a member of the *Parvovirus* genus of the family *Parvoviridae*, was first identified in 1978 \[[@r1], [@r14]\]. It has a small non-enveloped and icosahedral capsid containing single-stranded DNA. The CPV genome is approximately 5.2-kb \[[@r28]\] long and contains two open reading frames (ORFs). ORF1 encodes two non-structural proteins (NS1 and NS2) through alternative splicing of the transcribed viral mRNA, and ORF2 encodes two structural proteins (VP1 and VP2) \[[@r33]\]. The VP2 is the major capsid protein containing the antigenic determination sites to play an important role in determining CPV antigenic properties \[[@r17], [@r35]\]. CPV-2 is an epidemic enteric pathogen of dogs and causes acute gastroenteritis and lymphopenia mostly in puppies \[[@r26], [@r27]\]. A few years after CPV-2 outbreak, two new antigenic variants were characterized and termed as CPV-2a and CPV-2b to be the predominant type and were spread and distributed all over the world rapidly \[[@r28], [@r29]\]. In 2000, a new antigenic type of CPV was detected in Italy and rapidly spread to several countries \[[@r7]\].

It is difficult to diagnose CPV infection from the main clinical signs, such as vomiting and diarrhea, because these symptoms are common to other enteric diseases \[[@r12]\]. Some conventional methods used to detect CPV include electron microscopy, virus isolation \[[@r36]\], latex agglutination \[[@r3], [@r34]\], hemagglutination \[[@r19], [@r20], [@r36]\] and enzyme-linked immunosorbent assay (ELISA) \[[@r11], [@r15]\]. Many of these methods are effective and accurate in detecting viral infections in the laboratory. However, they are often laborious, time-consuming, expensive and/or lack specificity and sensitivity. With advances in molecular detection techniques, PCR \[[@r12], [@r37]\] and real-time PCR \[[@r8], [@r10], [@r14], [@r16]\] have been established for CPV diagnosis with a varying degree of sensitivity and specificity \[[@r9]\]. However, these techniques require skilled technicians and can only be performed in a diagnostic or commercial laboratory by employing specialized equipment not commonly available to veterinary clinics and impractical for use in the field. A rapid, accurate, sensitive, simple and economical on-site method is therefore needed for CPV detection, and one of the candidate methods is the technology of loop-mediated isothermal amplification (LAMP). The major advantages of LAMP comparing with conventional PCR are that (1) LAMP does not require a thermal cycler and can be performed simply with a heating block and/or water bath, (2) the reaction result of LAMP can be observed and justified by naked eyes, and (3) LAMP detection has a high sensitivity and can be completed within 1 hr under well experimental operation \[[@r21], [@r22], [@r24]\].

LAMP, first developed by Notomi *et al*. \[[@r24]\], is a powerful nucleic acid amplification technique that is sensitive and fast. It easily amplifies target sequences under isothermal conditions usually ranging from 60 to 65°C. In LAMP, specific primers are combined with *Bst* polymerase, which has strand displacement activity, to produce a large amount of amplified target DNA in \<1 hr. The amplified product can be analyzed by gel electrophoresis and/or visual inspection of turbidity resulting from the formation of the magnesium pyrophosphate by-product \[[@r22]\]. Accordingly, LAMP technology has been widely used for the detection of different pathogens \[[@r21]\]. To date, LAMP has been developed to diagnose canine viruses, including canine distemper virus (CDV) \[[@r5]\], rabies virus \[[@r4]\], influenza virus \[[@r13]\] and parvovirus \[[@r6], [@r23], [@r30]\]. LAMP has been found to be promising as a sensitive and cost-effective method for CPV detection.

Recent studies have shown that LAMP combined with ELISA and with lateral flow dipstick (LFD) are promising for application to pathogen diagnosis by visual field testing because they are nearly instrument-free \[[@r2], [@r31], [@r32]\]. However, the application of these detection methods remains to be explored in veterinary clinics. The objective of this study was to appropriately develop and evaluate a detection system based on the application of LAMP in conjunction with ELISA and LFD for convenient visual detection of CPV with high sensitivity and specificity.

MATERIALS AND METHODS {#s1}
=====================

*CPV strain and genomic DNA preparation*: The culture supernatant of CPV Strain C154 (CPV-2b) containing viral particles at 1 × 10^7^ TCID~50~/m*l* was kindly provided by Dr. C. K. Chuang of the Agricultural Technology Research Institute, Taiwan. The CPV suspension was serially diluted tenfold (10^6^--10^−2^ TCID~50~/m*l*), and the CPV genomic DNA was prepared from 100 *µl* of CPV supernatant using Viral Nucleic Acid Extraction Kit II (GeneDirex, Las Vegas, NV, U.S.A.), according to the manufacturer's instructions. The extracted DNA was subjected to PCR and LAMP.

*Design and synthesis of the primers and probe*: According to the published VP2 gene sequences of CPV \[[@r38]\] in GenBank (accession numbers including AB054213, AB054214, U72695, U72696, U72698, AB115504, D78585, M38245, FJ222821 and FJ005236) (including type 2a, 2b and 2c), sequences were aligned using the software program DNASTAR (Madison, WI, U.S.A.). The conserved sequence within the VP2 gene with high homology was selected as the target for designing the LAMP primer set using the software PrimerExplorer V4 (http://primerexplorer.jp/elamp4.0.0/index.html). A set of four specific primers was synthesized by MissionBiotech Inc. (Taipei, Taiwan). The primer pair, CPV-F (5′-biotin labeled) and CPV-R, was used as the PCR primer to amplify a 319-bp fragment ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Nucleotide sequences alignment of the VP2 gene from different CPV isolates including antigenic variants of type 2a, 2b and 2c. There were 5 (AB054213, AB054214, U72695, U72696 and U72698), 2 (AB115504 and D78585), 2 (M38245 and FJ005236) and 1 (FJ222821) CPV isolates from Taiwan, Japan, United State America and Italy, respectively. Partial sequences of the VP2 were aligned. The designed nucleic acid sequences of labeled-CPV-probe and primers were indicated, boxed and/or bolded.).

The region selected as the internal capture probe was located inside the forward inner primer (FIP)/backward inner primer (BIP) LAMP-amplified fragment of VP2 and labeled with biotin at the 5′ end (MDBio Inc., Taipei, Taiwan). The optimum hybridization temperatures for capture probes \[biotin-labeled probe for LAMP--ELISA or PCR--ELISA and fluorescein isothiocyanate (FITC)-labeled probe for LFD\] were also evaluated.

*PCR*: PCR was performed in a 25-*µl* volume containing 1 *µl* of CPV template DNA; 4 *µ*M of each primer; 200 *µ*M each of dATP, dCTP, dGTP and dTTP (Promega, Madison, WI, U.S.A.); 5 *µl* of 5 × PCR buffer (100 mM Tris-HCl, 9 mM MgCl~2~, 110 mM NH~4~Cl, 110 mM KCl, 0.3% IGEPAL CA-630 and 0.25% Tween 20, pH 8.9); 0.5 U of *OneTaq* DNA polymerase (New England BioLabs, Ipswich, MA, U.S.A.); and H~2~O. The PCR conditions were as follows: denaturation at 95°C for 5 min, followed by 35 cycles of denaturation at 95°C for 30 sec, annealing at 58°C for 45 sec, extension at 72°C for 45 sec and final extension at 72°C for a further 10 min. The amplified PCR products were analyzed by electrophoresis on a 2% agarose gel containing 0.5 *µ*g/m*l* ethidium bromide.

*LAMP*: LAMP was performed in a 20-*µl* volume containing 1.2 *µ*M each of FIP and BIP; 0.3 *µ*M each of the F3 and B3 primers; 10 *µl* of the 2 × reaction mixture (40 mM Tris-HCl, 20 mM KCl, 16 mM MgSO~4~, 20 mM (NH~4~)~2~SO~4~, 0.2% Tween 20, 1.6 M betaine and 2.8 mM dNTPs, pH 8.8); 1 *µl* template DNA; and 1 *µl* of *Bst* DNA polymerase (DNA Amplification Kit; Eiken Chemical Co., Tochigi, Japan). The reaction temperature was optimized by incubating the LAMP mixture at 59, 61, 63 or 65°C for 60 min. The reaction time was optimized by incubating the mixture for 15, 30, 45 and 60 min at a predetermined temperature (65°C). After heating at 80°C for 5 min to terminate the LAMP reaction, the LAMP products were analyzed by electrophoresis on a 2% agarose gel stained with ethidium bromide.

*CPV detection by the LFD assay*: A generic LFD strip (Milenia GenLine HybriDetect; Milenia Biotec GmbH, Gieβen, Germany) was used for the LFD assay. Under the test condition, a specific DNA probe was designed from the sequences between the F1P and B1P regions of LAMP amplicons ([Table 1](#tbl_001){ref-type="table"}Table 1.The information of primers and probes used in this study for the sequence detection of VP2 gene of canine parvovirusPrimers and probesNucleotide positionSequences (5'→3')Primer sets for LAMPCPV-F31409--1433GGGATAAAGAATTTGATACTGACTTCPV-B31627--1605GAGAGGCTCTTAGTTTAGCTTTABiotin-CPV-FIP (F1C-F2)1512--1488/1440--1461Biotin-AGGCGCAACTTTTACAAATAATTGAAAGACTTCATGTAAATGCACCACPV-BIP (B1C-B2)1530--1554/1595--1573TGATCCTGATGCATCTGCTAATATGTACCTTTCCACCAAAAATCTGAPrimer pair for PCRBiotin-CPV-F1375--1398Biotin-AATGTACCACCAGTTTATCCAAATCPV-R1666--1693TACTTGGTACATAGTTAAATTGGTTATCProbe for LAMP-ELISABiotin-CPV-probe1520--1546Biotin-CAAATGAATATGATCCTGATGCATCTGProbe for LAMP-LFDFITC-CPV-probe1520--1546FITC-CAAATGAATATGATCCTGATGCATCTG). According to the detection system established, the DNA probe was labeled with biotin or FITC at the 5′ end.

For this assay, 20 *p*mol of the FITC-labeled CPV probe was added to the biotin-labeled LAMP amplicons and hybridized at 58°C for 15 min. After hybridization, 8 *µl* of the reaction solution was mixed with 120 *µl* assay buffer, and the LFD strip was dipped into it for 5 min. The detection results were determined by observing the control and test lines on the LFD strips.

*PCR and LAMP amplicon detection combined with ELISA*: Detection using PCR--ELISA and LAMP--ELISA ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2.Schematic representation of PCR-ELISA and LAMP-ELISA assays. The biotin-labeled specific oligonucleotide probes are applied onto the surface of streptavidin-coated well and used to hybridize with biotin-labeled LAMP amplicons or biotin-labeled PCR products. After the nonspecific binding LAMP amplicons or biotin-labeled PCR products were removed, the conjugates of streptavidin- horseradish peroxidase (HRP) were added to perform the ELISA detection.) was conducted as described by Ravan *et al.* \[[@r32]\]. Each well of a 96-well microtiter plate (Nunc A/S, Roskilde, Denmark) was coated with 100 *µl* streptavidin (5 mg/m*l*; Sigma, St. Louis, MO, U.S.A.) in 10 mM phosphate-buffered saline (PBS, pH 7, Sigma) and refrigerated at 4°C overnight. The streptavidin-unbound sites were blocked with blocking solution \[1% (w/v) bovine serum albumin in PBS\] for 1 hr at room temperature. The plate was washed three times with PBST (PBS containing 0.05% Tween 20). Subsequently, each well received 100 *µl* of 2.5 *µ*M biotin-labeled CPV probe diluted in PBST. The plates were incubated at 37°C for 1 hr. After washing three times with PBST, the plate was subjected to PCR--ELISA or LAMP--ELISA.

After amplification, 5 *µl* of the PCR or LAMP amplicons were diluted with 95 *µl* hybridization solution (50 mM phosphate buffer and 2 mM EDTA, pH 7.2) and denatured at 95°C for 5 min. After cooling on ice, the denatured biotin-labeled PCR or LAMP amplicons were added to the capture probe--streptavidin-coated well and incubated at 58°C for 1 hr. After washing three times with PBST, 100 *µl* of a 1:1,000 dilution of streptavidin--horseradish peroxide (PerkinElmer, Waltham, MA, U.S.A.) in PBS was added to each well, and the plates were incubated at 37°C for 45 min. The wells were then washed five times with PBST, and the 3,3′,5,5′-tetramethylbenzidine liquid substrate system for ELISA (100 *µl,* Sigma) was added to each well. After incubation in the dark at room temperature, the reaction was stopped by adding 50 *µl* of 2 M H~2~SO~4~. Absorbance was detected at 450 nm using the TECAN/Sunrise ELISA reader (Advance Biotechnology, Taipei, Taiwan).

*Preparation of DNA from fecal samples artificially contaminated with CPV*: Five grams of a CPV-free dog fecal sample in 50 m*l* of sterile PBS was completely mixed by vortexing and distributed into 50 vials. Each vial contained a 1-m*l* aliquot of the fecal sample. The aliquots were inoculated with 100 *µl* CPV suspension (10^3^--10^−1^ TCID~50~/m*l*). The samples were centrifuged at 6,000 × *g* for 15 min, and the supernatant was collected. The supernatant was used for DNA extraction, and the samples were pretreated by rapid boiling and chilling as described previously \[[@r23]\]. Template DNA was prepared from the CPV-contaminated fecal samples using an Ultraclean Faecal DNA isolation kit (Mo Bio laboratories Inc., Carlsbad, CA, U.S.A.), according to the manufacturer's instructions.

RESULTS {#s2}
=======

*Establishment of the LAMP assay for CPV detection*: Several Taiwan isolates and strains from Japan, Italy and USA including antigenic types 2a, 2b and 2c were selected for developing effective visual detection methods for different CPV strains \[[@r38]\]. Given that the sequence of the VP2 gene of CPV is frequently used as the target for CPV detection, the PCR/LAMP primers were designed on the basis of the alignment of VP2 gene sequences from the selected strains.

According to alignment analysis, a highly conserved sequence was selected as a suitable target for designing the PCR/LAMP primers ([Fig. 1](#fig_001){ref-type="fig"}). A set of four primers capable of recognizing six distinct regions on the target sequence was designed: two outer primers (CPV-F3 and CPV-B3) and two inner primers (CPV-FIP and CPV-BIP). For ELISA and LFD analyses, the CPV-FIP primer was labeled with biotin at the 5′ end. Locations and sequences of the primers and specific probes for CPV detection are shown in [Fig. 1](#fig_001){ref-type="fig"} and [Table 1](#tbl_001){ref-type="table"}, respectively.

*Optimization of the LAMP assay*: When LAMP was performed to determine the optimal temperature and time of reaction, a ladder-like pattern of the LAMP products appeared on the 2% agarose gel at 59, 61, 63 and 65°C ([Fig. 3A](#fig_003){ref-type="fig"}Fig. 3.Optimization of loop-mediated isothermal amplification (LAMP) assay for the detection of VP2 sequence from CPV genomic DNA. (A) For the test of optimal temperature, reaction temperature of 65, 63, 61 and 59°C was tested using the genomic DNA extracted from 100 *µl* of CPV suspension (10^6^ TCID~50~/m*l*) as template. (B) For the interactive test of reaction time and template DNA concentration, the CPV genomic DNAs were extracted from 10^5^, 10^3^ and 10^1^ TCID~50~/m*l*, and then, each CPV genomic DNA was used in the LAMP reaction for 15, 30, 45 and 60 min. "N" indicated the negative control. "M" indicated the 100-bp ladder DNA marker, and the molecular of partial DNA ladders were also noted.). A slight difference in band clarity was observed with increasing reaction temperature. We selected 65°C as the optimal working temperature for LAMP, because of the intense signal and specificity observed at the higher temperature. The LAMP product could be amplified as early as 30 min when the template DNA concentration was high (isolated from 10^5^ TCID~50~/m*l* of CPV), whereas at a low template DNA concentration (10 TCID~50~/m*l* of CPV), the amplified LAMP was observed at 45 min at least ([Fig. 3B](#fig_003){ref-type="fig"}). We selected the optimal reaction condition of 65°C for 60 min to ensure positive detection at a low template DNA concentration.

*Sensitivity of PCR, LAMP and LAMP combined with the LFD assay*: To determine the sensitivity of CPV detection by LAMP and LAMP combined with LFD, the CPV stock (10^7^ TCID~50~/m*l*) was serially diluted tenfold, and the CPV genomic DNA was prepared from 100 *µl* of CPV supernatant. Each viral DNA (1 *µl*) was used as a template for conventional PCR or LAMP. In PCR, the respective dilutions were subjected to thermal cycling using the primer pair of biotin-labeled CPV-F and CPV-R ([Table 1](#tbl_001){ref-type="table"}), which amplified a 319-bp fragment from the VP2 gene of CPV ([Fig. 4A](#fig_004){ref-type="fig"}Fig. 4.Sensitivity of PCR (A), loop-mediated isothermal amplification (LAMP) (B), LAMP combined with enzyme-linked immunosorbent assay (ELISA) (C) and LAMP combined with lateral flow dipstick (LFD) (D) assays for the detection of VP2 sequence from CPV genomic DNA. The templates of CPV genomic DNA were extracted from CPV suspension ranging from 10^6^ to 10^−2^ TCID~50~/m*l*. "N" indicated the negative control, and "M" indicated the 100-bp DNA ladder marker.). In LAMP, a 20-*µl* reaction mixture was the same as for conventional LAMP; however, a 5′-biotinylated FIP was used to replace the FIP primer. The reaction was performed at 65°C for 60 min, and the products were analyzed by electrophoresis on a 2% agarose gel and the LFD assay. The results showed that PCR and LAMP could detect CPV at concentrations of 10^2^ TCID~50~/m*l* and 10^−1^ TCID~50~/m*l*, respectively ([Fig. 4A and 4B](#fig_004){ref-type="fig"}) and that LAMP--LFD was also able to detect CPV at concentrations as low as 10^−1^ TCID~50~/m*l* ([Fig. 4C](#fig_004){ref-type="fig"}). Thus, LAMP and LAMP--LFD were both 1,000 times more sensitive than conventional PCR.

*Sensitivity of PCR and LAMP combined with ELISA*: The genomic DNAs extracted from serially tenfold diluted CPV suspensions were used as templates for biotin-labeled PCR and LAMP. As described in Materials and methods, the labeled PCR products and LAMP amplicons were analyzed by ELISA. The overall scheme of PCR--ELISA and LAMP--ELISA is shown in [Fig. 2](#fig_002){ref-type="fig"}. The PCR--ELISA and LAMP--ELISA results were spectrophotometrically obtained using a microplate reader that provided an absorbance value corresponding to the amount of labeled PCR products or labeled LAMP amplicons attached to the surface of microtiter plate wells. In PCR--ELISA, a linear relationship (*y*~1~=−0.4064*x* + 2.127, *R^2^*=0.9833) was found at higher CPV titers, from 10^6^ to 10^2^ TCID~50~/m*l*. In LAMP--ELISA, CPV dilutions corresponding to 10^6^--10^2^ TCID~50~/m*l* gave a plateau absorbance value of OD~450~ ranging from 1.78 to 1.66, and a linear relationship (*y*~2~=−0.165*x* + 1.1216, *R^2^*=0.9869) was observed with CPV titers decreasing from 10^2^ to 10^−1^ TCID~50~/m*l* ([Fig. 5](#fig_005){ref-type="fig"}Fig. 5.Semi-quantification and limitation of LAMP-ELISA and PCR-ELISA for the detection of VP2 sequence from CPV genomic DNA. Different titers of CPV (10^6^ − 10^−2^ TCID~50~/m*l*) were applied to prepare the genomic DNA and then applied for PCR or LAMP amplification. The PCR products and LAMP amplicoms were used for the ELISA assays as the demonstration in [Fig. 2](#fig_002){ref-type="fig"}. Each value was derived from three independent detections, and the error bars mean standard deviation (SD).). It is indicated the detection limit of the developed PCR-ELISA and LAMP-ELISA was 10^2^ and 10^−1^ TCID~50~/m*l*, respectively.

*Specificity of LAMP detection by gel electrophoresis and LFD*: In order to evaluate the specificity of established LAMP, potential cross-reactions were performed using DNA/RNA extracted from different pathogens including CDV, infectious canine hepatitis virus (ICHV), *Leptospira canicola* and *Bordetella bronchiseptica*. Biotin-labeled LAMP amplicons were analyzed by 2% agarose gel electrophoresis with ethidium bromide and by the LFD assay. As shown in [Fig. 6A](#fig_006){ref-type="fig"}Fig. 6.Specificity of loop-mediated isothermal amplification (LAMP) (A) combined with lateral flow dipstick (LFD) (B) for the CPV detection. CPV genomic DNA, canine distemper virus (CDV) RNA, canine hepatitis virus (ICHV) genomic DNA, *B. bronchiseptica* genomic DNA and *L. canicola* genomic DNA were applied in the LAMP detections. "N" indicated the negative control. "M" indicated the DNA marker., cross-amplification tests using templates from CDV, ICHV, *L. canicola* and *B. bronchiseptica* showed that no amplicons were detected, whereas the reaction using the CPV template gave a positive result. The similar results were also observed in the LFD assay; the test band appeared only for CPV detection ([Fig. 6B](#fig_006){ref-type="fig"}). These results indicated that the LAMP-based assay methods developed in this study were specific for CPV.

*CPV detection in artificially contaminated dog fecal samples*: CPV was artificially inoculated into dog fecal samples and subjected to CPV detection by PCR--ELISA, LAMP--ELISA and LAMP--LFD. According to the results shown in [Table 2](#tbl_002){ref-type="table"}Table 2.Sensitivity of PCR-ELISA, LAMP-ELISA and LAMP-LFD assays for the CPV detection in artificially contaminated fecal sample of dogMethodsPBS\
(negative control)CPV inoculation (TCID~50~/m*l*) ^d)^10^--1^110^1^10^2^10^3^PCR-ELISA^a)^−−−−++LAMP-ELISA^b)^−−++++LAMP-LFD^c)^−−++++a) Positive was determined by the value of OD~450~\>0.261 determined by a spectrophotometry (as shown in [Fig. 6](#fig_006){ref-type="fig"}). b) Positive was determined by the value of OD~450~\>0.447 determined by a spectrophotometry (as shown in [Fig. 6](#fig_006){ref-type="fig"}). c) Positive was determined by yielding test band on LFD strip. d) Each CPV inoculation detected by different assays was performed from three independent fecal samples and got the same detection result., the fecal samples with CPV inoculated at ≥10^2^ TCID~50~/m*l* gave positive results by PCR--ELISA, and both LAMP--ELISA and LAMP--LFD provided positive results at ≥1 TCID~50~/m*l* of CPV. Importantly, the positive signals produced by all of the detection methods including PCR--ELISA, LAMP--ELISA and LAMP--LFD could be easily read with the naked eye.

DISCUSSION {#s3}
==========

Several detection methods have been developed to detect CPV proteins and nucleic acids, and many of these tests are effective and accurate in detecting the viral infection in laboratory. However, they require expensive equipment and are often laborious and time-consuming. Early and rapid diagnosis is necessary so that CPV-infected dogs can be isolated to prevent the spread of the disease and to administer supportive treatment for reducing morbidity and mortality. Therefore, a novel nucleic acid amplification method, termed LAMP, which amplifies specific DNA sequences under isothermal conditions within a few hours, was developed as a simple, rapid, specific and cost-effective alternative \[[@r24]\]. LAMP is an excellent technology for the detection of nucleic acids present at very low levels in biological and environmental samples with its remarkable sensitivity. Therefore, LAMP could be applied to gene analysis and study of genetic traits and mostly to detect etiological cause of infections.

In the present study, the CPV detection limit by PCR, PCR-ELISA, LAMP, LAMP--ELISA and LAMP--LFD was 10^2^, 10^2^, 10^−1^, 10^−1^ and 10^−1^ TCID~50~/m*l*, respectively. The results indicated that the sensitivity of LAMP--ELISA and LAMP--LFD for CPV detection is higher than that of conventional molecular methods. The results could be easily visualized with the naked eye. In addition to reducing assay time and elevating the sensitivity, combination of LAMP with ELISA or with LFD confirmed amplicon identity by hybridization and eliminates the need to handle, such as ethidium bromide.

Our results confirmed the previous report of CPV detection from CPV-suspected fecal samples by LAMP having a detection limit of 10^−1^ TCID~50~/m*l* \[[@r6]\] and to show that LAMP is more sensitive than PCR-based tests. We have demonstrated this consistently in the present study. Our results also showed that LAMP--ELISA was more sensitive than PCR--ELISA; a positive signal was detected at 10^2^ TCID~50~/m*l* by PCR--ELISA, while LAMP--ELISA provided a positive signal at 10^−1^ TCID~50~/m*l*. Furthermore, the performance of LAMP and PCR diagnostic systems has been extensively compared by several groups. According to the report of Cho *et al*. \[[@r6]\], the detection rates of CPV-suspected fecal samples by LAMP and PCR were 80% and 74%, respectively. Mukhopadhyay *et al*. \[[@r23]\] also compared the detection rates of CPV by LAMP and PCR from clinical samples to be 74.28% and 57.85%. In general, LAMP has been found to have sensitivity similar or superior to that of PCR \[[@r18], [@r25], [@r32]\]. We have demonstrated this consistency of the 12 clinical samples tested and 10 (83%) and 8 (67%) were detected positive for CPV by LAMP and PCR, respectively (data not shown). The positive results of CPV detection could be presented fully when LAMP combined with ELISA and LFD. However, immunization with modified-live CPV vaccine may result in shedding of the virus for a period of 3 to 14 days post vaccination. Therefore, it is possible that there is a positive result that can be produced by a recent CPV vaccination with our developed LAMP--ELISA and LAMP--LFD assays.

In the present report, we described the development of LAMP--ELISA and LAMP--LFD diagnostic systems with an assay time of \<3 hr for CPV levels of clinical concern with a pretty high sensitivity. We have known the most commercial test kits for CPV diagnosis are fabricated by the immunochromatographic assay or ELISA technology. The detection by the kits can be completed within mins, but the detection limit of the kits is approximate 10^3^ TCID~50~/m*l* of CPV in canine feces. The purpose of our study was to develop a highly sensitive assay used to detect the canine CPV as possible as early after the virus infection. Early detection is a key in the control of virus transmission among dogs. Although the overall detection time is about 3 hr including sample preparation and detection, the test procedure of the developed LAMP--ELISA and LAMP--LFD assays is easy to be performed and can be used in field test. Our system comprised the amplification of a part of VP2 sequences that is unique to CPV, followed by hybridization to a specific probe for exact identification of CPV. Our results confirmed the results of recent reports that indicated LAMP--ELISA or LAMP--LFD to be highly-sensitive methods that can be easily applied for the visual detection of clinical pathogens \[[@r2], [@r32]\]. The high sensitivity of LAMP--ELISA and LAMP--LFD may allow the identification of dogs shedding CPV at low titers in their feces, helping veterinarians to adopt adequate measures of prophylaxis to prevent CPV infection.

Our data also showed that the CPV detection limit for artificially contaminated fecal samples using LAMP--ELISA and LAMP--LFD was ≥1 TCID~50~/m*l*. This sensitivity was lower than the results shown in [Figs. 4](#fig_004){ref-type="fig"},[5](#fig_005){ref-type="fig"} and [Table 2](#tbl_002){ref-type="table"}. We suggest that the lower sensitivity of CPV detection in fecal samples than in PBS may be related to loss of the virus during isolation of CPV from the fecal samples. It may also be related to the presence of intestinal cells and bacteria along with CPV in the prepared DNA, which might have reduced the efficiency of LAMP in amplifying the target CPV DNA from the samples. However, our results indicated that both LAMP--ELISA and LAMP--LFD developed in the present study are applicable to CPV detection in naturally contaminated fecal samples.

In conclusion, when LAMP was combined with ELISA or with LFD, the detection signal of LAMP amplicons could be spectrophotometrically obtained and easily read with the naked eye and without agarose gel electrophoresis. The assays could be completed within 3 hr. To our knowledge, this is the first report employing LAMP combined with ELISA or LFD for detection of CPV. These results indicated that a simple and cost-effective LAMP-based technique can be developed into a rapid and reliable molecular diagnostic method with potential for routine use in the clinical detection of CPV and other veterinary clinical pathogens.

This study was supported by the grant of 102-EC-17-A-02-04-0454 from the Ministry of Economic Affairs of Executive Yuan, Taiwan, R.O.C. The authors gratefully thank Dr. Chin-Kai Chuang for kindly providing CPV.
